Earnings roundup: Celgene, Alexion, Amgen

Celgene Corp. (NASDAQ:CELG), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Amgen Inc. (NASDAQ:AMGN) reported earnings Thursday.

Celgene beat 3Q16 estimates and raised full-year 2016 guidance for both adjusted EPS and revenues. The company now expects adjusted EPS of $5.88-$5.92 on revenues of $11.2 billion for the year, up from the previous estimates of $5.70-$5.75 and $11 billion. Sales of multiple myeloma drug Revlimid lenalidomide were nearly $1.9 billion for the quarter, up 30% from 3Q15. The company now expects $7 billion in Revlimid sales this year. Adjusted 3Q16 EPS was $1.58 on total revenues of $2.98 billion, beating the consensus of $1.48 per share on $2.83 billion in revenues. ...